Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Collegium Pharmaceutical Inc

Healthcare US COLL

33.38USD
0.69(2.11%)

Last update at 2026-06-05T20:00:00Z

Day Range

33.0134.25
LowHigh

52 Week Range

25.9850.79
LowHigh

Fundamentals

  • Previous Close 32.69
  • Market Cap1078.18M
  • Volume333286
  • P/E Ratio19.23
  • Dividend Yield-%
  • EBITDA419.16M
  • Revenue TTM780.57M
  • Revenue Per Share TTM24.62
  • Gross Profit TTM 693.64M
  • Diluted EPS TTM1.73

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 92.62M 98.57M 75.73M -28.84700M -3.37400M
Minority interest - - - - -
Net income 62.87M 69.19M 48.16M -25.00200M 71.52M
Selling general administrative 284.80M 172.32M 151.80M 172.19M 118.96M
Selling and marketing expenses - 10.66M 7.41M - -
Gross profit 463.26M 377.34M 326.17M 209.49M 150.62M
Reconciled depreciation 226.07M 169.16M 149.26M 138.94M 68.92M
Ebit 174.93M 172.54M 159.07M -104.57300M -46.69900M
Ebitda 401.00M 341.70M 308.33M 34.37M 22.22M
Depreciation and amortization 226.07M 169.16M 149.26M 138.94M 68.92M
Non operating income net other - - - 1.05M 0.01M
Operating income 187.08M 169.90M 166.96M -104.57300M -46.69900M
Other operating expenses 593.48M 461.55M 399.81M 430.61M 254.66M
Interest expense 82.31M 73.97M 83.34M 63.21M 21.01M
Tax provision 29.75M 29.38M 27.58M -3.84500M -74.89100M
Interest income 11.29M 13.98M 15.62M 1.05M 0.01M
Net interest income -71.02300M -59.99800M -67.72400M -62.16600M -21.00200M
Extraordinary items - - - - -
Non recurring - - - - 4.58M
Other items - - - - -
Income tax expense 29.75M 29.38M 27.58M -3.84500M -74.89100M
Total revenue 780.57M 631.45M 566.77M 463.93M 276.87M
Total operating expenses 276.17M 207.45M 159.21M 176.17M 128.41M
Cost of revenue 317.31M 254.10M 240.60M 254.44M 126.25M
Total other income expense net -94.46500M -71.32700M -91.22800M 75.73M 43.33M
Discontinued operations - - - - -
Net income from continuing ops 62.87M 69.19M 48.16M -25.00200M 71.52M
Net income applicable to common shares - - - -25.00200M 71.52M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1656.83M 1663.59M 1143.31M 1174.13M 692.08M
Intangible assets 669.51M 891.40M 421.71M 567.47M 268.72M
Earning assets - - - - -
Other current assets 32.64M 55.39M 0.09M 16.68M 0.03M
Total liab 1355.16M 1434.75M 947.88M 979.29M 489.15M
Total stockholder equity 301.68M 228.84M 195.43M 194.84M 202.93M
Deferred long term liab - - - - -
Other current liab 398.30M 424.54M 264.90M 66.88M 147.83M
Common stock 0.04M 0.04M 0.04M 0.04M 0.04M
Capital stock 0.04M 0.04M 0.04M 0.04M 0.04M
Retained earnings -101.12900M -163.99900M -233.18900M -281.34400M -256.34200M
Other liab - - - - -
Good will 145.93M 162.33M 133.86M 133.69M -
Other assets - - - 19.33M 942.74M
Cash 251.10M 70.56M 238.95M 173.69M 186.43M
Cash and equivalents - - - - -
Total current liabilities 440.03M 509.51M 457.92M 270.11M 230.40M
Current deferred revenue 0.67M 10.00M - - -
Net debt 689.46M 788.73M 435.34M 699.10M 72.32M
Short term debt 30.41M 65.85M 184.32M 163.61M 49.17M
Short long term debt 29.00M 64.58M 183.33M 162.50M 48.35M
Short long term debt total 940.56M 859.30M 674.28M 872.79M 258.75M
Other stockholder equity 402.44M 392.75M 428.57M 476.15M 459.23M
Property plant equipment - - - 19.52M 19.49M
Total current assets 691.41M 482.26M 537.60M 419.99M 315.54M
Long term investments - - - - -
Net tangible assets - - - -506.32100M -65.79500M
Short term investments 155.43M 92.20M 71.60M - -
Net receivables 211.33M 228.54M 179.53M 183.12M 105.84M
Long term debt 780.33M 787.90M 483.84M 538.45M 201.63M
Inventory 40.91M 35.56M 32.33M 46.50M 17.39M
Accounts payable 10.66M 3.93M 8.69M 39.62M 33.40M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.32M 0.06M 0.01M - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.04M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -281.34400M -256.34200M
Treasury stock - - - - -42.86100M
Accumulated amortization - - - - -
Non currrent assets other 20.19M 9.41M 0.83M 2.65M 2.63M
Deferred long term asset charges - - - - -
Non current assets total 965.42M 1181.33M 605.71M 754.14M 376.53M
Capital lease obligations 5.54M 6.81M 7.11M 8.22M 8.77M
Long term debt total - - - 538.45M 201.63M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -61.79200M -287.75900M -46.65500M -573.69100M -1.94400M
Change to liabilities - - - -11.83800M -1.05000M
Total cashflows from investing activities -63.53200M -287.75900M -70.81200M -573.69100M -1.94400M
Net borrowings -70.38300M 7.52M -65.91800M -75.00000M -50.00000M
Total cash from financing activities -110.24500M -60.60300M -140.17800M 436.72M -89.30300M
Change to operating activities - - - -38.50000M 44.13M
Net income 62.87M 69.19M 48.16M -25.00200M 71.52M
Change in cash 155.55M -143.38200M 63.76M -12.73800M 12.31M
Begin period cash flow 96.61M 239.99M 176.24M 188.97M 176.66M
End period cash flow 252.16M 96.61M 239.99M 176.24M 188.97M
Total cash from operating activities 329.32M 204.98M 274.75M 124.23M 103.56M
Issuance of capital stock - - - - -
Depreciation 220.82M 169.16M 149.26M 138.94M 68.92M
Other cashflows from investing activities - - - -572.06900M -
Dividends paid - - 9.10M - -
Change to inventory -5.35300M 13.93M 14.17M 48.27M -2.29600M
Change to account receivables 17.20M -4.41400M 3.59M -21.78000M -22.52400M
Sale purchase of stock -25.10400M -60.02500M -75.00000M -14.06300M -47.86100M
Other cashflows from financing activities -20.40100M -8.09700M 0.74M 513.98M 8.56M
Change to netincome - - - 14.48M -53.78700M
Capital expenditures 1.74M 1.65M 0.46M 1.62M 1.94M
Change receivables - - - -21.78000M -22.52400M
Cash flows other operating - - - 109.12M 39.37M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -12.73800M 12.31M
Change in working capital 3.76M -54.97800M 21.73M -12.71300M 13.49M
Stock based compensation 41.91M 32.40M 27.14M 22.87M 24.25M
Other non cash items 25.62M 16.02M 30.62M 8.52M 3.42M
Free cash flow 327.58M 203.33M 274.29M 122.61M 101.61M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
COLL
Collegium Pharmaceutical Inc		 0.69 2.11% 33.38 19.23 4.55 1.38 3.68 1.97 3.84
ZTS
Zoetis Inc		 -0.08 0.10% 79.44 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -1.13 3.48% 31.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -5.4 3.30% 158.31 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.13 0.32% 40.45 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical Inc

100 Technology Center Drive, Stoughton, MA, United States, 02072

Key Executives

Name Title Year Born
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. Co-Founder & Chairman 1964
Mr. Joseph J. Ciaffoni Pres, CEO & Director 1971
Ms. Colleen Tupper Exec. VP & CFO 1976
Ms. Shirley R. Kuhlmann Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. 1984
Mr. Scott Dreyer Exec. VP & Chief Commercial Officer 1973
Dr. Richard Malamut M.D. Exec. VP & Chief Medical Officer 1960
Ms. Alex Dasalla Head of Investor Relations NA
Mr. Bart J. Dunn Exec. VP of Strategy & Corp. Devel. NA
Ms. Marlo Manning Head of HR NA
Mr. Scott Sudduth Head of Technical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.